María Angeles Lima

TL;DR: A review of clinical studies on LAMB for VL and other forms of leishmaniasis is provided, finding it to be highly efficacious and safe in over 8000 VL patients treated by MÉdecins Sans Frontières in South Asia, and its use was feasible even at primary healthcare level.

TL;DR: This is the largest cohort of VL patients treated with 20 mg/kg Ambisome worldwide and has high initial and long-term efficacy, and a low rate of adverse reactions when administered under field conditions in Bihar, India.

TL;DR: The VL epidemic expanded rapidly over a several-year period, culminating in an epidemic peak in the last third of 2005, spread over two districts, and transformed into a sustained endemic situation by 2007.

TL;DR: Even after initial cure following treatment with AmBisome, these patients appear to have much higher rates of VL relapse and mortality than patients not known to be HIV-positive, although relapse rates appear to stabilize after 2 years.

TL;DR: In this paper, the authors present information about the age, gender, weight, and height of 29,570 consecutive leishmaniasis patients presenting to 20 locations in six geographic endemic regions of Brazil, East Africa, Nepal, and India between 1997 and 2009.